Investigators say adding RNA interference (RNAi) therapy to current treatment modalities may improve outcomes in patients with acute myeloid leukemia (AML) with internal tandem duplication in the ...

Secondary acute myeloid leukemia (AML) is a blood cancer that arises from other blood disorders or previous cancer treatment. Those with secondary AML tend to have a less favorable outlook than ...

When resistance to or failure of hypomethylating agents (HMAs) occurs in acute myeloid leukemia (AML), depleting a ligase called TOPORS may help. Because TOPORS is not directly druggable at ...

Acute myeloid leukemia is one of the deadliest cancers. Leukemic stem cells responsible for the disease are highly resistant to treatment. A new editorial paper was published in Oncotarget's ...

With the acute phase of the Covid-19 pandemic fading even as the coronavirus persists and evolves, a new normal is taking shape around the world. Experts worry the unusual move, driven by vaccine ...

The technology accurately detects the presence of these gene fusions in acute promyelocytic leukemia ... Radon, Even at Levels Below EPA Guideline for Mitigation, Is Linked to Childhood Leukemia ...

Teachers and staff at McCourt Middle School, as well as the community at-large, took solidarity to a new level last Thursday, Oct. 31, during their Golden Glow Day ...

Acute myeloid leukemia is a type of blood cancer in which the bone marrow makes excess numbers of abnormal immature white blood cells known as myeloblasts. Myelodysplastic syndrome refers to a ...

while AXL inhibition in macrophages may enhance the myeloid-centered anti-leukemia immune response. Dr. Kiyean Nam, CEO of Qurient, conveyed his enthusiasm for the company’s strategic trajectory ...

About Aptevo Therapeutics Inc. Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for the treatment of cancer. Aptevo is seeking ...